Investing.com - Denali Therapeutics (NASDAQ: DNLI) reported second quarter EPS of $-0.59, $0.08 better than the analyst estimate of $-0.67. Revenue for the quarter came in at $1.5M versus the consensus estimate of $10M.
Denali Therapeutics's stock price closed at $24.37. It is up 42.18% in the last 3 months and down -13.10% in the last 12 months.
Denali Therapeutics saw 3 positive EPS revisions and 2 negative EPS revisions in the last 90 days. See Denali Therapeutics's stock price’s past reactions to earnings here.
According to InvestingPro, Denali Therapeutics's Financial Health score is "good performance".
Check out Denali Therapeutics's recent earnings performance, and Denali Therapeutics's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar